Effects of immunosuppressive treatment on patient outcomes after immune checkpoint inhibitor-related gastrointestinal toxicity

[1] Abu-Sbeih H(2018)The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients’ outcomes J Immunother Precis Oncol 1 7-18

[2] Tang T(2019)Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma Cancer Immunol Immunother 68 553-561

[3] Ali FS(2018)Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer J Clin Oncol 36 2872-2878

[4] Johnson DH(2018)Understanding the tumor immune microenvironment (TIME) for effective therapy Nat Med 24 541-550

[5] Qiao W(2018)(2018) Mucosal microbiome dysbiosis in gastric carcinogenesis Gut 67 1024-1032

[6] Diab A(2017)Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis Aliment Pharmacol Ther 46 213-224

[7] Wang Y(2011)The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights Mol Cell Endocrinol 335 2-13

[8] Abu-Sbeih H(2022)Comparative long-term drug survival of vedolizumab, adalimumab, and infliximab in biologic-naïve patients with ulcerative colitis Dig Dis Sci 12 7041-527

[9] Ali FS(2021)Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance Nat Commun 6 519-357

[10] Qiao W(2020)Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive Pembrolizumab or placebo: a secondary analysis of a randomized clinical trial JAMA Oncol 114 356-894

[1] Abu-Sbeih H(2018)The impact of immune checkpoint inhibitor-related adverse events and their immunosuppressive treatment on patients’ outcomes J Immunother Precis Oncol 1 7-18

[2] Tang T(2019)Immune checkpoint inhibitor-induced colitis as a predictor of survival in metastatic melanoma Cancer Immunol Immunother 68 553-561

[3] Ali FS(2018)Impact of baseline steroids on efficacy of programmed cell death-1 and programmed death-ligand 1 blockade in patients with non-small-cell lung cancer J Clin Oncol 36 2872-2878

[4] Johnson DH(2018)Understanding the tumor immune microenvironment (TIME) for effective therapy Nat Med 24 541-550

[5] Qiao W(2018)(2018) Mucosal microbiome dysbiosis in gastric carcinogenesis Gut 67 1024-1032

[6] Diab A(2017)Systematic review with meta-analysis: faecal microbiota transplantation for the induction of remission for active ulcerative colitis Aliment Pharmacol Ther 46 213-224

[7] Wang Y(2011)The anti-inflammatory and immunosuppressive effects of glucocorticoids, recent developments and mechanistic insights Mol Cell Endocrinol 335 2-13

[8] Abu-Sbeih H(2022)Comparative long-term drug survival of vedolizumab, adalimumab, and infliximab in biologic-naïve patients with ulcerative colitis Dig Dis Sci 12 7041-527

[9] Ali FS(2021)Glucocorticoid receptor regulates PD-L1 and MHC-I in pancreatic cancer cells to promote immune evasion and immunotherapy resistance Nat Commun 6 519-357

[10] Qiao W(2020)Association between immune-related adverse events and recurrence-free survival among patients with stage III melanoma randomized to receive Pembrolizumab or placebo: a secondary analysis of a randomized clinical trial JAMA Oncol 114 356-894